This fully-updated third edition of Scleroderma: From Pathogenesis to Comprehensive Managementbuilds upon the well-regarded approach in the previous editions to provide integrated, concise, and up-to-date synthesis of current concepts of pathogenesis and modern approaches to management of systemic sclerosis (scleroderma). With a multidisciplinary approach to comprehensive care, this book is easily accessible for health care professionals in many fields. Comprised of the authoritative work of international experts, the new edition includes extensive updated material reflecting major developments in the field. It presents a succinct and thoughtful synthesis of current pathomechanistic concepts, providing a valuable reference tool for basic and translational investigators working in the field. Scleroderma: From Pathogenesis to Comprehensive Management serves as an essential, all-inclusive and fully up to date resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients.
Preface.- . Foreword.- Section 1: Introduction. .-
1. Historical
perspective of scleroderma.- Section 2: Epidemiology, Genetics and
Classification. .-
2. Epidemiology, Environmental and Infectious Risk
Factors.-
3. Influence of ethnicity and sex bias in systemic sclerosis.-
4.
Genetic Factors.-
5. Classification and Disease Subsets in Clinical
Practice.-
6. Clustering and evolving concepts for subclassification.-
7. The
Clinical Aspects of Autoantibodies.-
8. Systemic sclerosis overlap
syndromes.-
9. Juvenile Localized and Systemic Scleroderma.-
10. Morphea
(Localized scleroderma).- Section 3: The Biological Basis of Systemic
Sclerosis. .-
11. Scleroderma Mimics.-
12. Introduction: The Etiopathogenesis
of Systemic Sclerosis - an Integrated Overview.-
13. Pathology of Systemic
Sclerosis.-
14. Inflammation And Immunity In Systemic Sclerosis.-
15.
Autoantibodies as Markers and Possible Mediators of Scleroderma
Pathogenesis.-
16. Mechanisms of Vascular Disease.-
17. Biomarkers in
Systemic Sclerosis.-
18. Cellular and molecular mechanisms of fibrosis in
systemic sclerosis.-
19. Overview of Animal Models.- Section 4:
Cardiovascular Manifestations and Management. .-
20. Overview of management
and outcome assessment in systemic sclerosis.-
21. Raynauds Phenomenon,
Digital Ulcers and Nailfold Capillaroscopy.-
22. Renal crisis and other renal
manifestations.-
23. Cardiac Involvement: Evaluation And Management.- Section
5: Pulmonary Manifestations and Management. .-
24. Overview of lung
involvement.-
25. Clinical assessment of ILD.-
26. Lung Imaging Perspective
in Scleroderma.-
27. Treatment of Interstitial Lung Disease in systemic
sclerosis.-
28. Pathogenesis of Pulmonary Arterial Hypertension.-
29.
Clinical Assessment of Pulmonary Hypertension.-
30. The management of
pulmonary arterial hypertension in the setting of systemic sclerosis.-
Section 6: Gastrointestinal Manifestations and Management. .-
31. Overview of
gastrointestinal tract involvement.-
32. UpperGastrointestinal Tract:
Manifestations of Systemic Sclerosis.-
33. Lower Gastrointestinal Tract
Involvement: Understanding the Interplay of Motility, the Microbiome and
Nutrition.- Section 7: Skin, Musculoskeletal and Other Complications. .-
34.
Evaluation and Management of Skin Disease.-
35. Calcinosis.-
36. Tendons,
Joints, and Bone.-
37. Skeletal Muscle Involvement.-
38. Cancer in Systemic
Sclerosis.-
39. Overlooked Manifestations.-
40. Pregnancy.-
41. Vaccinations
in Patients with Systemic Sclerosis.- Section 8: Management and Outcome
Assessment.-
42. Management Of Progressive Skin Involvement In Diffuse
Scleroderma.-
43. Hematopoietic stem cell transplantation.-
44. Immune
targeted therapies in SSc..-
45. Physical and Occupational Therapy.-
46.
Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Section
9: Case Studies: Approach to Complex Clinical Problems. .-
47. Measuring
Disease Activity and Outcomes in Clinical Trials.-
48. Evolving clinical
trial design andinnovative approaches.-
49. Drug Development and Regulatory
Considerations for Systemic Sclerosis Therapies.-
50. Managing the Ischemic
Finger in Scleroderma.-
51. Scleroderma Renal Crisis: a case study.-
52.
Rapid diffuse skin disease with progressive joint contractures.-
53.
Management of the Scleroderma Patient with Pulmonary Arterial Hypertension
Failing Initial Therapy.-
54. Pseudo-obstruction with malabsorption and
malnutrition.-
55. Progressive Interstitial Lung Disease Non-Responsive to
Immunosuppressive Therapy.-
56. Body Image Distress in Scleroderma.-
57.
Managing Complicated Digital Ulcers.-
58. Lower Limb Ulceration.
Yannick Allanore
Service de Rhumatologie A,
Universit. Paris Descartes, Hôpital Cochin
Paris, France.
John Varga
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan, USA
Christopher P. Denton
Centre for Rheumatology
The Royal Free Hospital
London, United Kingdom
Masataka Kuwana
Department of Allergy and Rheumatology
Nippon Medical School
Tokyo, Tokyo, Japan
Lorinda Chung
Stanford Medicine
Rheumatology
Redwood City
California, USA
Ami Shah
Clinical and Translational Research
Johns Hopkins Hospital
Baltimore, Maryland, USA
